ANALYSIS OF THE FLT3-ITO AND NPM1 MUTATIONS IN AML PATIENTS WITH INTERMEDIATE RISK RECEIVING ALLOGENEIC STEM-CELL TRANSPLANTATION

被引：0
|
作者：
Ogasawara, M. [1 ]
Yamakawa, T. [1 ]
Katsura, Y. [1 ]
Shima, K. [1 ]
Matsukawa, T. [1 ]
Kanaya, M. [1 ]
Minauchi, K. [1 ]
Nakata, M. [1 ]
Ota, S. [1 ]
Imai, K. [1 ]
Hirano, T. [1 ]
Kobayashi, N. [1 ]
Kiyama, Y. [1 ]
机构：
[1] Sapporo Hokuyu Hosp, Sapporo, Hokkaido, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2010.12.432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
396
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant
    Salem, Rana
    Massoud, Radwan
    Mahfouz, Rami
    Bazarbachi, Ali
    El Cheikh, Jean
    BLOOD, 2016, 128 (22)
  • [2] Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant
    R Salem
    R Massoud
    B Haffar
    R Mahfouz
    A Bazarbachi
    J El-Cheikh
    Bone Marrow Transplantation, 2017, 52 : 1187 - 1190
  • [3] Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant
    SalemRana, R.
    Massoud, R.
    Mahfouz, R.
    Bazarbachi, A.
    El-Cheikh, J.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S341 - S342
  • [4] Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant
    Salem, R.
    Massoud, R.
    Haffar, B.
    Mahfouz, R.
    Bazarbachi, A.
    El-Cheikh, J.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1187 - 1190
  • [5] The value of allogeneic stem cell transplantation in patients with intermediate risk (ELN) acute myeloid leukemia with no FLT3-ITD, no NPM1 mutations and no CEBPA double mutations
    Heidrich, K.
    Thiede, C.
    Schaefer-Eckart, K.
    Schmitz, N.
    Aulitzky, W. E.
    Kraemer, A.
    Roesler, W.
    Haenel, M.
    Einsele, H.
    Baldus, C. D.
    Trappe, R. U.
    Stoelzel, F.
    Middeke, J. M.
    Roellig, C.
    Taube, F.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S81 - S81
  • [6] The value of allogeneic stem cell transplantation in patients with intermediate risk (ELN) Acute Myeloid Leukemia with no FLT3-ITD, no NPM1 mutations and no CEBPA double mutations
    Heidrich, K.
    Thiede, C.
    Schaefer-Eckart, K.
    Schmitz, N.
    Aulitzky, W. E.
    Kraemer, A.
    Roesler, W.
    Haenel, M.
    Einsele, H.
    Baldus, C. D.
    Trappe, R. U.
    Stoelzel, F.
    Middeke, J. M.
    Roellig, C.
    Taube, F.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 28 - 28
  • [7] Allogeneic stem cell transplantation for patients with AML and FLT-3 mutations
    Schleuning, M.
    Judith, D.
    Heshmat, M.
    Burlakova, I.
    Tschischka, S.
    Baurmann, H.
    Schwerdtfeger, R.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S274 - S275
  • [8] Clinical relevance of NPM1 and FLT3 mutations in AML patients
    Blau, O.
    Baldus, C. D.
    Graul, K.
    Sindram, A.
    Thiel, E.
    Blau, I. W.
    ONKOLOGIE, 2010, 33 : 234 - 234
  • [9] Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
    Schwind, Sebastian
    Bischof, Lara
    Bill, Marius
    Grimm, Juliane
    Ussmann, Jule
    Gaston, Elizabeth
    Backhaus, Donata
    Brauer, Dominic
    Herling, Marco
    Merz, Maximilian
    Metzeler, Klaus H.
    Franke, Georg-Nikolaus
    Vucinic, Vladan
    Platzbecker, Uwe
    Jentzsch, Madlen
    BLOOD, 2022, 140 : 3412 - 3413
  • [10] NPM1 mutations are valid minimal residual disease parameters following allogeneic stem cell transplantation: A study on 116 AML patients
    Bacher, Ulrike
    Badbaran, Anita
    Zander, Axel R.
    Fehse, Boris
    Kroger, Nicolaus
    BLOOD, 2007, 110 (11) : 493A - 494A
12345